N@N

Cubist Pharmaceuticals to Present at August 2011 Investor Conferences

^{Published on 2011-07-26 10:35:47 - Market Wire}
 

LEXINGTON, Mass.--([ BUSINESS WIRE ])--[ Cubist Pharmaceuticals, Inc. ] (NASDAQ: CBST) today announced that company management will host 1-on-1 meetings at one and present at another investor conference during August 2011 to discuss the companya™s business activities, financial outlook, and current news.

• David McGirr, SVP and CFO, will host one-on-one meetings on Tuesday, August 2, at the Goldman Sachs Small Caps One-on-One Summit at the Langham Hotel in Boston. Mr. McGirr will be joined by Eileen C. McIntyre, Senior Director, Investor Relations. These meetings will not be webcast.
• Robert Perez, EVP and COO, will present on Tuesday, August 16, at 9:10 a.m. ET at the Wedbush Securities 2011 Life Sciences Management Access Conference at the Le Parker Meridien in New York. The live webcast will be accessible through Cubista™s website at [ www.cubist.com ] in the Investor Relations Conference Calendar section, and it will be available for viewing at that location for 30 days after the presentation.

About Cubist

Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address significant unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN® (daptomycin for injection), the first antibiotic in a class of anti-infectives called lipopeptides, and has an agreement with Optimer Pharmaceuticals, Inc. to co-promote DIFICIDa" in the U.S. as a treatment of CDAD (Clostridium difficile-associated diarrhea) in adults. The current Cubist clinical development pipeline includes CXA-201, a novel cephalosporin in combination with tazobactam in development for the treatment of certain serious infections caused by multi-drug resistant (MDR) Gram-negative organisms. CXA-201 is in Phase 3 trials for complicated urinary tract infections (cUTI), and Cubist expects to initiate Phase 3 trials with CXA-201 in complicated intra-abdominal infections (cIAI) by the end of 2011. In addition, Phase 3 trials of CXA-201 in hospital acquired (nosocomial) pneumonia are expected to begin in 2012. Cubist has completed Phase 2 trials of a novel antibacterial candidate, CB-183,315, for the treatment of CDAD and plans to make a go/no go decision of whether to move CB-183,315 into Phase 3 trials in the third quarter of 2011. Cubist also is working on several pre-clinical programs being developed to address areas of significant medical needs. These include therapies to treat various serious bacterial infections and acute pain. Cubist is headquartered in Lexington, Mass. Additional information can be found at Cubista™s web site at [ www.cubist.com ].

Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc.

DIFICID is a trademark of Optimer Pharmaceuticals, Inc.